BACKGROUND: Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor. It is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). This dose schedule is associated with myelosuppression and pleural effusions. Anecdotal data suggest that lower doses may be as effective and less toxic. The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP. METHODS: Seventy-five patients with newly diagnosed CML-CP received dasatinib 50 mg daily. The eligibility and response criteria were standards used in previous protocols. RESULTS: At a median follow-up of 9 months, 60 patients were evaluable for a response at 3 months. The rates of patients achieving BCR-ABL1 transcript levels 10% and 1% at 3 months by the International Standard were 93% and 72%, respectively. The rates of complete cytogenetic response by conventional cytogenetics or fluorescence in situ hybridization at 6 and 12 months were 86% and 88%, respectively. At 12 months, 79%, 71%, and 46% of the patients had achieved a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction, respectively. Nine patients had a dose interruption for 14 days. Only 1 patient developed a pleural effusion requiring a dose reduction to 20 mg. All patients remained alive and with no transformation so far. CONCLUSION: Dasatinib 50 mg daily is active and well tolerated in patients with newly diagnosed CML-CP. It should be further explored as a new potential standard-of-care option for chronic myeloid leukemia. Cancer 2018;124:2740-7.
INTRODUCTION
The therapeutic landscape of chronic myeloid leukemia (CML) changed dramatically with the development of small molecule tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1. The 10-year survival rate for patients with chronic myeloid leukemia in chronic phase (CML-CP) improved from approximately 20% to between 80% and 90%. 1 Four TKIs-imatinib, nilotinib, dasatinib, and, most recently, bosutinib-have been approved for frontline therapy for patients with newly diagnosed CML-CP. [1] [2] [3] Therapy with second-generation TKIs has been reported to provide significantly deeper and faster responses with no impact on long-term survival. 3, 4 Dasatinib is an oral second-generation TKI that is 325 times more potent than imatinib in vitro. [5] [6] [7] It also inhibits the Src family of kinases, which may be important in blunting critical cell signaling pathways. 8 Dasatinib was initially evaluated in patients in the salvage setting and was later compared with imatinib and approved for frontline CML therapy. 2 A 5-year follow-up showed that dasatinib induced more rapid and deeper responses at early time points in comparison with imatinib. 4 At 3 months, a higher proportion of patients treated with dasatinib achieved BCR-ABL1 transcripts (International Standard [IS]) 10% (84% vs 64%; P < .0001). 9 Dasatinib induced higher 12-month confirmed complete cytogenetic response (CCyR) rates (77% vs 66%; P 5 .007) and higher 5-year cumulative major molecular response (MMR) rates (76% vs 64%; P < .0022) and molecular response with a 4.5-log reduction (MR4.5) rates (42% vs 33%; P 5 .025). Pleural effusions occurred more frequently with dasatinib therapy (28% vs < 1%). 4 Additional side effects encountered with dasatinib included myelosuppression (20%) and rarely pulmonary hypertension (5%).
In early clinical trials evaluating dasatinib, the drug was noted to be active at lower doses with a better safety profile. 10 In a randomized trial of 4 dose schedules of dasatinib (100 vs 140 mg daily; and a single-dose schedule vs a twice daily schedule), a 100-mg single daily dose of dasatinib was found as effective as 140 mg daily with a better safety profile. 11 Furthermore, investigators from the Dasatinib Versus Imatinib Study in Treatment-Na€ ıve Chronic Myeloid Leukemia Patients (DASISION) reported the ability to maintain the efficacy of dasatinib among patients who had their dose reduced while improving its safety profile. 12 The aim of this study was to evaluate a lower dose of dasatinib, 50 mg daily, in patients with newly diagnosed CML. Lower doses may improve efficacy by improving drug exposure and minimizing drug interruptions due to adverse events. In addition, this strategy may prove to be more cost-effective, particularly with the availability of generic formulations of imatinib.
MATERIALS AND METHODS
Patients with a new diagnosis of Philadelphia chromosome (Ph)-positive CML-CP (a diagnosis within 12 months of the start of the study treatment) were eligible. Patients should have received no prior CML therapy other than hydroxyurea or a maximum of 1 month of therapy with a TKI. Prior therapy with 1 to 2 doses of cytarabine was allowed. Other eligibility criteria included an age 18 years, a performance status of 0 to 2, and adequate organ function. Patients with clonal evolution were eligible as long as they met all other criteria for chronic-phase disease (blasts < 15%, blasts plus promyelocytes < 30%, basophils < 20%, and platelets > 100 3 10 9 /L unless related to therapy). Patients with uncontrolled angina within 3 months, diagnosed with or suspected to have congenital long QT syndrome, with any history of clinically significant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or torsade de pointe) with a prolonged QTc interval on a pre-entry electrocardiogram (>460 milliseconds), or with a history of a significant bleeding disorder unrelated to CML were not eligible. The study was approved by the institutional review board; all patients signed an institutional review board-approved informed consent form.
Patients received dasatinib at 50 mg once daily. Treatment was continued until disease progression or unacceptable toxicity. Patients with a grade 3 to 4 nonhematologic toxicity had their treatment transiently interrupted, and dasatinib was restarted (after resolution to grade 1 or lower) with 1 dose-level reduction to 40 mg once daily. As for hematologic toxicity, treatment was interrupted for grade 4 neutropenia (neutrophils < 0.5 3 10 9 /L) or thrombocytopenia (platelets < 40 3 10 9 /L). Treatment was restarted at the same dose if a recovery to above these levels occurred within 2 weeks. Treatment was restarted with a reduction of 1 dose level if the recovery time was >2 weeks.
Patients who did not achieve BCR-ABL1 transcripts (IS) 10% by 3 months, CCyR after 6 months (Ph fluorescence in situ hybridization [FISH] positivity 2%; BCR-ABL1 transcripts [IS] 1%), or MMR after 12 months of therapy (BCR-ABL1 transcripts [IS] 0.1%) and had experienced no grade 3 or higher toxicity could have the dasatinib dose escalated to 100 mg daily. These patients would be counted as failures for the purpose of statistical monitoring described later.
Patients were monitored by routine blood counts with differential and blood chemistry every 1 to 2 weeks for the first month and then every 4 to 8 weeks thereafter. Bone marrow aspiration with cytogenetic analysis and peripheral blood quantitative reverse transcription-polymerase chain reaction (PCR) for BCR-ABL1 transcripts were performed at the baseline, and then peripheral blood FISH and PCR were performed for BCR-ABL1 transcripts every 3 months for 1 year and every 6 months thereafter. From patient 19 onward, a confirmatory conventional cytogenetic analysis was performed at 6 months. For FISH testing, 200 cells were routinely counted. Response criteria were as previously defined. 13 CCyR was defined as 0% Ph-positive metaphases based on Gbanding with at least 20 metaphases counted, as FISH positivity 2%, or as BCR-ABL1 transcripts (IS) 1%. As the data matured and showed discrepant results between FISH testing and PCR at 3 months and on the basis of the published literature, we used BCR-ABL1 transcripts (IS) 1% to define CCyR. Molecular responses were categorized as follows: MMR, which was defined as BCR-ABL1 transcripts (IS) 0.1%, and MR4.5, which was defined as BCR-ABL1 transcripts (IS) 0.0032% with a detection sensitivity 1 in 10 5 cells. 13 The IS conversion factor at our institution is 30.35. Therefore, a patient reported to have BCR-ABL1 transcripts < 0.01% has a converted value of BCR-ABL1 transcripts (IS) of < 0.01% 3 0.35, which equals < 0.0035%. This is interpreted as equivalent to 0.0032% or equal to MR4.5. Patients with reported BCR-ABL1 transcripts of 0.01% have a converted value of BCR-ABL1 transcripts (IS) of 0.01% 3 0.35, which equals 0.0035% and is still considered a molecular response with a 4.0-log reduction (MR4.0) for the purpose of this analysis. This was a pilot study (NCT02689440) initially designed to enroll 50 patients. An additional 25 patients were enrolled to assess and confirm the efficacy. The primary objective was to meet a target MMR rate of 50% at 12 months. This was based on historical experience with dasatinib.
14 Two endpoints were monitored: the MMR probability at 12 months and the toxicity rate. The secondary endpoint was to meet a target CCyR rate of 75% at 6 months. The goal was to determine whether a lower dose of dasatinib would at least maintain the same efficacy as standard-dose dasatinib (100 mg daily) with a better safety profile. Seventy-five patients were to be treated, with early stopping rules for responses and toxicity. The study would stop if, at any time during the study, it was determined that there was more than a 5% chance that the MMR probability at 12 months would be less than 50% and there was more than a 5% chance that the CCyR probability at 6 months would be less than 75%. For toxicity monitoring, the study would stop if, at any time during the study, it was determined that there was more than a 95% chance that the rate of grade 3 or higher toxicities would be more than 20%. This evaluation would be done at 6 months. These stopping rules for responses and toxicity would be applied from the beginning with the first patient enrolled and in cohorts of 10.
RESULTS

Patient and Treatment Characteristics
Between March 2016 and November 2017, 75 patients were consecutively treated. Baseline characteristics are summarized in Table 1 . The median age was 47 years (range, 19-84 years). The median time from diagnosis to treatment was 6 days (range, 0-40 days). Fifteen patients (20%) had received a TKI for less than 28 days before enrollment-8 with dasatinib, 5 with imatinib, and 2 with nilotinib-with a median time on prior TKI therapy of 19 days (range, 1-29 days). According to the Sokal risk score, 49 patients (65%) had a low risk, 20 (27%) had an intermediate risk, and 6 (8%) had a high risk. The median follow-up time for all patients was 9 months (range, 0.7-21.2 months). The data cutoff was November 2017.
Response and Outcome
Overall, 2 patients discontinued therapy: the first patient 5 days after treatment initiation because of a traumatic brain bleed and the second patient because of a failure to achieve CCyR and MMR at 12 months into therapy. Fifteen patients were observed for less than 3 months. Of the 75 patients who started therapy on low-dose dasatinib, 60 were observed for 3 months and were thus evaluable for cytogenetic and molecular responses. Table 2 lists the rates of responses at 3, 6, 9, and 12 months. For this analysis, all 60 evaluable patients were kept in the denominator up to the time of their last follow-up, with patients who discontinued therapy included up to the follow-up time that would correspond to the time of this report had they stayed in the study. Therefore, all rates were calculated at the time point rather than as cumulative rates (by the time point). This is a more conservative form of reporting responses in comparison with previous trials (reporting cumulative rates). Sixty patients reached the 3-month follow-up, 50 patients reached the 6-month follow-up, 34 patients As the data matured and showed a discrepancy between PCR and fluorescence in situ hybridization testing at 3 months, a BCR-ABL1 transcript level (IS) 1% was used to define CCyR. In addition, a cytogenetic assessment by conventional cytogenetics was mandated at 6 months; this started with patient 19.
reached the 9-month follow-up, and 24 patients reached the 12-month follow-up. Responses occurred early in the study. At 3 months, 56 of the 60 patients (93%) had achieved BCR-ABL1 transcripts (IS) 10%, and 43 of the 60 patients (72%) had achieved BCR-ABL1 transcripts (IS) 1%, which was equivalent to CCyR. At 6 months, 43 of the 50 patients (86%) had achieved CCyR. The rates of CCyR with 95% confidence intervals (CIs) at 6, 9, and 12 months after the initiation of dasatinib treatment were 86% (95% CI, 73%-94%), 85% (95% CI, 69%-95%), and 88% (95% CI, 68%-97%), respectively. At 12 months, 19 of the 24 patients (79%) had achieved MMR. The rates of MMR at 3, 6, 9, and 12 months after the initiation of dasatinib were 28% (95% CI, 17%-41%), 66% (95% CI, 51%-79%), 82% (95% CI, 65%-93%), and 79% (95% CI, 58%-93%), respectively. At 12 months, 17 of the 24 patients (71%) and 11 of the 23 patients (46%) had achieved MR4.0 and MR4.5, respectively. There was a rapid reduction in transcript levels with median BCR-ABL1 transcripts (IS) of 0.34% (range, 0.007%-12.9%) at 3 months, 0.02% (range, 0%-11.2%) at 6 months, and 0.0035% (range, 0%-9.5%) at 12 months. At 12 months, CCyR had been achieved by 88% of the patients, MMR had been achieved by 79%, MR4.0 had been achieved by 71%, and MR4.5 had been achieved by 46%. The median time to CCyR was 3.2 months (range, 2.7-6.3 months), the median time to MMR was 5.8 months (range, 2.7-9.0 months), and the median time to MR4.5 was 7.6 months (range, 5.7-12.6 months).
Two patients did not meet the milestones per protocol specifications (a failure to achieve a cytogenetic response at 6 months) and had the dasatinib dose increased to 100 mg daily. These patients were considered to be treatment failures. Neither of the 2 patients tested positive for ABL kinase domain mutations. The first patient was noted to have a decline in hemoglobin to 6 g/dL and a platelet level of 60 3 10 9 /L 8 weeks into treatment with dasatinib at the 100-mg daily dose. The workup for anemia was negative. Dasatinib was held for 3 weeks and resumed with the recovery of blood counts with a dose reduction to a 70-mg daily dose. At the 12-month follow-up, repeat bone marrow examination showed persistent disease without evidence of a cytogenetic or molecular response. No ABL kinase domain mutations were detected. The patient was subsequently taken off the study because of a lack of a response to dasatinib therapy. The second patient did not achieve a cytogenetic response at 6 months. Dasatinib was increased to 100 mg daily. Two patients were taken off the study: In addition to the first patient already described (taken off the study because of a lack of a response), a second patient was taken off the study because of a traumatic brain bleed 4 days into therapy (withholding dasatinib was judged by the treating physician to be in the patient's best interest).
So far, the responses have been durable: none of the patients who achieved CCyR and MMR in the study lost their response to therapy. All patients were alive at the time of this writing, and none had disease transformation to an accelerated or blast phase. In comparison with historical data (the DASISION trial) for patients treated with imatinib (n 5 260) or dasatinib 100 mg daily (n 5 259), the results with lower doses of dasatinib were more favorable. 4 Higher rates of CCyR and MMR were noted with dasatinib 50 mg daily versus dasatinib 100 mg daily and imatinib (Fig. 1) . 2, 4 An early response to therapy with BCR-ABL1 transcripts (IS) 10% and 1% at 3 months was also noted to be higher with lower dose dasatinib in comparison with historical data with dasatinib 100 mg and imatinib (Fig. 2) . 
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Low-Dose Dasatinib for Early Chronic-Phase CML/Naqvi et al Cancer July 1, 2018 An interesting observation was the discrepant results between the PCR and FISH studies at 3 months. FISH positivity 2% (equivalent to CCyR) at 3 months was observed in 26 of the 60 patients (43%; 3 patients had FISH positivity 2% at 3 months and BCR-ABL1 transcripts [IS] > 1%). BCR-ABL1 transcripts (IS) 1% (also equivalent to CCyR) at 3 months was observed in 43 of the 60 patients (72%). However, 20 of these 43 patients who achieved BCR-ABL1 transcripts (IS) 1% at 3 months had FISH positivity > 2% (Table 3 ). In fact, 7 of these patients had achieved MMR despite testing positive by FISH. This highlights the limitation of peripheral blood FISH testing at 3 months, which possibly gives rise to false results. Because of this finding, we subsequently amended the study to have a bone marrow cytogenetic evaluation instead of FISH testing at 6 months for the assessment of a cytogenetic response. Among 12 of the 20 patients who reached the 6-month evaluation, 11 had achieved CCyR: 9 by conventional cytogenetic analysis (4 patients had both conventional cytogenetics and FISH and tested negative; 5 had conventional cytogenetics alone and tested negative) and 2 by FISH alone. One patient had a partial cytogenetic response. The remaining 8 of the 20 patients were receiving dasatinib and had not yet reached the 6-month evaluation at the time of this writing.
Safety
Treatment was well-tolerated overall. Nine patients (12%) had a dose interruption for 14 days in the first 3 months of therapy: 2 for a lower gastrointestinal bleed, 2 for renal dysfunction, 2 for transaminitis, and 3 for thrombocytopenia. Treatment was resumed (after resolution to grade 1 or lower) without any dose modification.
Only 1 patient with a prior dose interruption for renal dysfunction (secondary to dehydration) at the time of the 3-month follow-up visit developed a pleural effusion and required a dose reduction to 20 mg daily. The patient remained on 20 mg daily without any recurrence of the pleural effusion. One patient, who was 75 years old, had traumatic subdural bleeding on day 4 from the start of therapy. This was unlikely related to dasatinib, but the patient was taken off the study on day 5 of dasatinib and was not evaluable for a response.
DISCUSSION
In this study, dasatinib 50 mg daily in patients with early CML-CP was effective and safe. Eighty-six percent of the patients had achieved CCyR at 6 months from the start of therapy. The 12-month MMR rate was 79%; the 12-month MR4.5 rate was 46%. Treatment was well tolerated, with only 9 patients (12%) requiring treatment interruption for 14 days (range, 7-14 days). A pleural effusion was encountered in only 1 patient (1% so far), who required a dose reduction to 20 mg. These results compare favorably with the historical experience at our institution in similar patients treated with standard-dose dasatinib as well as the DASISION study. 4, 14, 15 In the 5-year follow-up of the DASISION study, 28% of the patients developed dasatinib-related pleural effusions, which required drug interruption in 62% and/or a dose reduction in 41% of the cases. 4 Responses with low-dose dasatinib occurred considerably faster and ultimately at higher rates in comparison with responses reported with standard-dose dasatinib. For example, the 6-month CCyR rate with dasatinib at 50 mg daily was 86%, which was higher than that reported with standard-dose dasatinib (73% at 6 months) and with imatinib (59% at 6 months).
Discordance was noted between BCR-ABL1 transcripts (IS) 1% and FISH testing at 3 months. Similar discordances were reported in the DASISION trial when responses at 3 and 6 months were being assessed. 9 One possible explanation of this discordance could be related to the fact that our PCR analysis may not accurately reflect the amount of disease in patients at early milestones (eg, at 3 months) with transcript levels < 1%. With further follow-up at 6 months, a higher level of concordance was observed. To limit this discordance, the protocol was amended to include cytogenetic analysis by the Gbanding technique at 6 months to confirm the CCyR.
We have previously reported on the favorable impact of the achievement of 3-and 6-month CCyR and BCR-ABL1 transcripts (IS) 1% on long-term event-free and progression-free survival in patients treated with second-generation TKIs in the frontline setting. 9, 16 In the current study, the 3-and 6-month rates of BCR-ABL1 transcripts (IS) 1% were 72% and 84%, respectively, in contrast to the rates of 48% and 69% with dasatinib 100 mg and the rates of 13% and 49% with imatinib 400 mg in historical series. 9 Furthermore, the 12-month MMR and MR4.5 rates (79% and 46%) were significantly higher than the rates obtained with standard-dose dasatinib (46% and 5%, respectively). 4 Although a higher percentage of patients in the current study were low risk according to the Sokal score, the distribution was similar to what has been reported in our previous studies with dasatinib and nilotinib. 14, 17 The high efficacy of this strategy may, therefore, reside in the safety profile of low-dose dasatinib with minimal treatment interruptions and constant drug exposure. Previous studies have shown that treatment interruptions correlate with worse outcomes.
These extrapolations should be considered with caution because the comparisons refer to historical controls. Moreover, the follow-up is still limited. The inclusion criteria for all these studies (imatinib and standard-dose dasatinib) were identical, and there were no obvious differences in the patient characteristics.
14 The long-term impact of low-dose dasatinib as initial therapy for CML will require a longer follow-up. However, the results reported here appear to be encouraging in comparison with those achieved with other second-generation TKIs. 4, 18, 19 The high rate of MR4.5 may play a crucial role in treatment discontinuation. Several studies have evaluated whether TKIs can be safely discontinued in patients who have achieved long-term deep molecular responses. Higher treatment-free remission rates can be achieved with low-dose dasatinib because of the deeper and more sustained molecular responses achieved with this strategy in comparison with imatinib and standard-dose secondgeneration TKIs. In the European Stop Tyrosine Kinase Inhibitor (EURO-SKI) study, the largest study to date of TKI discontinuation in CML, among 821 patients with CML treated with frontline imatinib, nilotinib, or dasatinib who had achieved at least MR4.0 and had subsequently stopped TKI therapy, the molecular recurrencefree survival rate at 2 years was 52%. 20 In a multivariate analysis, a duration of MR4.0 of 3 or more years was the only significant factor for a persistent deep molecular response after therapy was stopped. Additional factors include a duration of TKI therapy of 6 or more years. 21 The low-dose dasatinib strategy induced the highest rates of deep molecular responses so far and may be preferred as the initial therapy for patients in whom eventual TKI discontinuation may be particularly valued (eg, younger patients expected to live for 2 or more decades and who may benefit from TKI discontinuation).
Lower dose dasatinib constitutes a cost-effective strategy. It may allow the achievement of an optimal response at a lower cost than standard-dose dasatinib. Recently, generic formulations of imatinib became available, although at a higher cost than expected. 22, 23 Despite the availability of 4 imatinib generics in the United States in 2017, the average wholesale price of a year of any generic imatinib is $110,000 versus $140,000 or more for patented imatinib. The price of generic imatinib is $3000 to $8000 per year in Canada and $400 per year in India. With proper market forces in the United States, historically, the price of a generic drug was expected to decrease to 10% of the patented drug's price once 4 or more generics were available. Thus, the current experience with generic imatinib is unusual or raises the perception of potentially unusual market forces. The average wholesale price is $170,000 or more for a year of dasatinib at 100 mg versus $96,000 for dasatinib at 50 mg. Therefore, lower dose dasatinib offers an optimal solution with at least equivalent efficacy in comparison with secondgeneration TKIs but at a significant lower cost, a price currently even lower than generic formulations of imatinib in the United States.
Today, most patients with CML-CP are functionally cured with long-term TKI therapy. Strategies should be explored to increase the proportion of patients who achieve treatment-free remissions. Carter et al reported on emerging data suggesting that the combination of Bcl-2 inhibitors (venetoclax) with TKIs enhanced cytotoxicity, depleted CML stem cells, and prolonged survival in a murine CML model. 24, 25 Such a strategy may lead to a potentially higher percentage of patients who achieve long-term complete molecular remissions and a treatment-free remission status. A study combining dasatinib 50 mg daily with venetoclax in frontline CML-CP is planned.
In summary, dasatinib at 50 mg daily was effective and safe as initial therapy for CML-CP. High rates of responses and rapid achievement of CCyR were observed in nearly all patients after 6 months from the start of therapy. The 12-month MMR and MR4.5 rates of 79% and 46%, respectively, were encouraging. The results were achieved with very favorable toxicity profiles. Dasatinib 50 mg daily may be considered a new cost-effective option for frontline therapy in CML-CP. A confirmation of these findings is warranted. A randomized study comparing 50 mg of dasatinib with the standard dose could be considered. 
FUNDING SUPPORT
